Price$45.99+0.66 (+1.46%)
01:30 PM07:45 PM
News · 26 weeks92-64%
2025-12-282026-06-21
Mix4490d
- Insider19(43%)
- Other12(27%)
- SEC Filings11(25%)
- Earnings2(5%)
Latest news
25 items- PRAlkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Narcolepsy Type 2 — — Improvements in Wakefulness and Patient-Reported Cognition and Fatigue Were Sustained Through 13 Weeks — — Alixorexton Was Generally Well Tolerated at All Doses Tested — Alkermes plc (NASDAQ:ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the study's dual primary endpoints, demonstrating statistically significant and cl
- SECAlkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
- PRAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and EuropeAlkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug designations (ODD) from leading regulatory bodies in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) has granted ODD to alixorexton for the treatment of IH, and the European Commission has granted ODD to alixorexton for the treatment of narcolepsy. "Narcolepsy and idiopathic hypersomnia are rare, chronic neurological conditions for which significant unmet need remains. These orphan drug des
- INSIDERDirector Wright Christopher I sold $90,200 worth of Ordinary Shares (2,000 units at $45.10) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 25,680 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDEREVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $87,564 worth of Ordinary Shares (2,034 units at $43.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 229,524 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- PRAlkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research— 26 Abstracts Accepted Demonstrate Alkermes' Commitment to Advancing Understanding and Treatment of Narcolepsy and Idiopathic Hypersomnia — — Detailed Positive Results from Vibrance-2 Phase 2 Study of Alixorexton, an Orexin 2 Receptor Agonist, in Patients With Narcolepsy Type 2 to be Shared in Oral Presentation — Alkermes plc (NASDAQ:ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-rele
- PRAlkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceAlkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. A
- INSIDEREVP R&D, Chief Medical Officer Hopkinson Craig C. sold $375,044 worth of Ordinary Shares (9,000 units at $41.67) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $19.34, decreasing direct ownership by 5% to 77,389 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERVP, Finance (Interim PAO) Parisi Samuel Joseph sold $687,007 worth of Ordinary Shares (16,217 units at $42.36) and exercised 16,217 units of Ordinary Shares at a strike of $19.48 (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- PRAlkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — Alkermes plc (NASDAQ:ALKS) today announced plans to present clinical and real-world data related to the company's psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes' proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 receptor agonists, including alixorexton, ALKS 4510 and ALKS 72
- INSIDERDirector Wright Christopher I converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 20% to 27,680 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Wilson Frank Anders covered exercise/tax liability with 1,475 units of Ordinary Shares and converted options into 6,142 units of Ordinary Shares, increasing direct ownership by 15% to 35,751 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Snyderman Nancy Lynn Md converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 44% to 15,395 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Mckeon Brian P converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 14% to 38,536 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Lurker Nancy converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 34% to 18,222 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Laurencin Cato T converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 16% to 33,769 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Gaynor Richard4/A - Alkermes plc. (0001520262) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Cooke Shane4/A - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Gaynor Richard converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 15% to 35,751 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- INSIDERDirector Cooke Shane converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 3,207 units of Ordinary Shares, increasing direct ownership by 3% to 106,679 units (SEC Form 4)4 - Alkermes plc. (0001520262) (Issuer)
- PRAlkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences– Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative Symptoms and Outcomes From Four Years of Treatment, and Real-World Evidence From Use of LYBALVI (olanzapine and samidorphan) in Clinical Practice – Alkermes plc (NASDAQ:ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing
- SECAlkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alkermes plcSCHEDULE 13G/A - Alkermes plc. (0001520262) (Subject)
- SECSEC Form DEFA14A filed by Alkermes plcDEFA14A - Alkermes plc. (0001520262) (Filer)
- SECAlkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Alkermes plc. (0001520262) (Filer)
ALKS FAQ
7 questionsWhat does Alkermes plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA...Where does ALKS stock trade?
Alkermes plc (ALKS) is listed on NASDAQ.What sector and industry is ALKS in?
Alkermes plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alkermes plc go public?
Alkermes plc (ALKS) completed its IPO in 1991.What are analysts saying about ALKS?
Alkermes plc has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $4500.00 price target on 2026-02-24. Recent price targets range from $4000.00 to $4500.00.What companies are similar to ALKS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALKS side-by-side with any of them on Quantisnow.How can I track ALKS on Quantisnow?
Quantisnow aggregates Alkermes plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALKS to receive live email and push alerts on every new disclosure.